Keira Annie Markey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2105989/publications.pdf

Version: 2024-02-01

60 3,909 33 57
papers citations h-index g-index

63 63 63 2236 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). Journal of Neurology, 2022, 269, 1945-1956.	3.6	17
2	Cerebrospinal fluid shunting protocol for idiopathic intracranial hypertension for an improved revision rate. Journal of Neurosurgery, 2022, 136, 1790-1795.	1.6	8
3	Managing idiopathic intracranial hypertension in pregnancy: practical advice. Practical Neurology, 2022, 22, 295-300.	1.1	17
4	Increased systemic and adipose $11\hat{1}^2$ -HSD1 activity in idiopathic intracranial hypertension. European Journal of Endocrinology, 2022, 187, 323-333.	3.7	11
5	Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 2019-2027.	2.3	17
6	Erenumab for headaches in idiopathic intracranial hypertension: A prospective openâ€abel evaluation. Headache, 2021, 61, 157-169.	3.9	31
7	$11\hat{l}^2$ HSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 174-187.	3.6	39
8	Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure. Brain Communications, 2021, 3, fcab202.	3.3	26
9	The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension. Neurology: Clinical Practice, 2021, 11, e504-e507.	1.6	38
10	Migraine: disease characterisation, biomarkers, and precision medicine. Lancet, The, 2021, 397, 1496-1504.	13.7	141
11	Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. Journal of Headache and Pain, 2021, 22, 39.	6.0	39
12	The Role of Metabolism in Migraine Pathophysiology and Susceptibility. Life, 2021, 11, 415.	2.4	14
13	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight, 2021, 6, .	5.0	45
14	Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 2021, 17, 501-514.	10.1	194
15	Outcomes measures in idiopathic intracranial hypertension. Expert Review of Neurotherapeutics, 2021, 21, 687-700.	2.8	12
16	Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension. JAMA Neurology, 2021, 78, 678.	9.0	86
17	Headache attributed to idiopathic intracranial hypertension and persistent postâ€idiopathic intracranial hypertension headache: A narrative review. Headache, 2021, 61, 808-816.	3.9	37

#	Article	IF	Citations
19	Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system. Surgery for Obesity and Related Diseases, 2021, 17, 1310-1316.	1.2	15
20	Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 795-797.	1.9	28
21	Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. Eye, 2020, 34, 1321-1333.	2.1	9
22	Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. Journal of Headache and Pain, 2020, 21, 116.	6.0	24
23	Emerging themes in idiopathic intracranial hypertension. Journal of Neurology, 2020, 267, 3776-3784.	3.6	27
24	Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension. JAMA Ophthalmology, 2020, 138, 1264.	2.5	43
25	New horizons for idiopathic intracranial hypertension: advances and challenges. British Medical Bulletin, 2020, 136, 118-126.	6.9	23
26	European headache federation consensus on the definition of resistant and refractory migraine. Journal of Headache and Pain, 2020, 21, 76.	6.0	126
27	$11\hat{l}^2$ -Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Communications, 2020, 2, fcz050.	3.3	46
28	Idiopathic intracranial hypertension: Update on diagnosis and management. Clinical Medicine, 2020, 20, 384-388.	1.9	29
29	Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: Minimal gain, is it worth the pain?. Cephalalgia, 2019, 39, 245-253.	3.9	51
30	Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom. JAMA Neurology, 2019, 76, 1088.	9.0	79
31	What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open, 2019, 9, e026573.	1.9	48
32	Tip of the iceberg in idiopathic intracranial hypertension. Practical Neurology, 2019, 19, 178-179.	1.1	5
33	United Kingdom CSF Disorders Day 2018. Neuro-Ophthalmology, 2019, 43, 131-134.	1.0	0
34	Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension. Current Opinion in Neurology, 2019, 32, 422-431.	3.6	27
35	Advances in the understanding of headache in idiopathic intracranial hypertension. Current Opinion in Neurology, 2019, 32, 92-98.	3.6	61
36	The expanding burden of idiopathic intracranial hypertension. Eye, 2019, 33, 478-485.	2.1	148

3

#	Article	IF	CITATIONS
37	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCl Insight, $2019,4,.$	5.0	55
38	Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. Journal of Neuro-Ophthalmology, 2018, 38, 522-530.	0.8	78
39	WED 097â€Diagnostic lumbar punctures in IIH: what is the patient experience?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A10.2-A10.	1.9	0
40	European Headache Federation guideline on idiopathic intracranial hypertension. Journal of Headache and Pain, 2018, 19, 93.	6.0	111
41	Evaluation and management of adult idiopathic intracranial hypertension. Practical Neurology, 2018, 18, 485-488.	1.1	38
42	Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. BMJ Open, 2018, 8, e020445.	1.9	37
43	Idiopathic intracranial hypertension: consensus guidelines on management. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1088-1100.	1.9	303
44	Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol. BMJ Open, 2017, 7, e017426.	1.9	63
45	A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Science Translational Medicine, 2017, 9, .	12.4	71
46	Disability from posttraumatic headache is compounded by coexisting posttraumatic stress disorder. Journal of Pain Research, 2017, Volume 10, 1991-1996.	2.0	11
47	Assessing the Efficacy and Safety of an $11\hat{l}^2$ -Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e181.	1.0	33
48	CHARACTERISING FAT DISTRIBUTION AND RESPONSE TO WEIGHT LOSS IN IIH. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.208-e1.	1.9	0
49	Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurology, The, 2016, 15, 78-91.	10.2	321
50	Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 982-992.	1.9	173
51	Headache determines quality of life in idiopathic intracranial hypertension. Journal of Headache and Pain, 2015, 16, 521.	6.0	79
52	Should we educate about the risks of medication overuse headache?. Journal of Headache and Pain, 2014, 15, 10.	6.0	26
53	$11\hat{l}^2$ -Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 2013, 34, 525-555.	20.1	152
54	Migraine, cerebrovascular disease and the metabolic syndrome. Annals of Indian Academy of Neurology, 2012, 15, 72.	0.5	16

#	Article	IF	CITATION
55	Rating papilloedema: an evaluation of the Frisén classification in idiopathic intracranial hypertension. Journal of Neurology, 2012, 259, 1406-1412.	3.6	83
56	A randomised controlled trial of treatment for idiopathic intracranial hypertension. Journal of Neurology, 2011, 258, 874-881.	3.6	118
57	NMRâ€based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases – a diagnostic tool?. NMR in Biomedicine, 2010, 23, 123-132.	2.8	105
58	Cerebrospinal Fluid Corticosteroid Levels and Cortisol Metabolism in Patients with Idiopathic Intracranial Hypertension: A Link between $11\hat{l}^2$ -HSD1 and Intracranial Pressure Regulation?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5348-5356.	3.6	84
59	Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ: British Medical Journal, 2010, 341, c2701-c2701.	2.3	257
60	Exploring the pathogenesis of IIH: An inflammatory perspective. Journal of Neuroimmunology, 2008, 201-202, 212-220.	2.3	74